Morgan Stanley Maintains Equal-Weight on Acelyrin, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit has maintained an Equal-Weight rating on Acelyrin (NASDAQ:SLRN) but has lowered the price target from $13 to $6.
August 19, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Acelyrin but significantly lowered the price target from $13 to $6, indicating a less optimistic outlook.
The reduction in price target from $13 to $6 by a major analyst like Morgan Stanley suggests a negative outlook, which could lead to short-term downward pressure on Acelyrin's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100